Seronegative Sicca Syndrome: Diagnostic Considerations and Management Strategies
- PMID: 40566617
- PMCID: PMC12194705
- DOI: 10.3390/life15060966
Seronegative Sicca Syndrome: Diagnostic Considerations and Management Strategies
Abstract
Seronegative sicca syndrome encompasses patients who present with xerostomia and/or keratoconjunctivitis sicca but lack anti-SSA/SSB antibodies and do not fulfill current classification criteria for primary Sjögren's syndrome (pSS). Despite symptom overlap with pSS, these individuals remain diagnostically and therapeutically unclassified. This review studies the clinical, immunological, and pathological spectrum of seronegative sicca, highlighting its heterogeneity and the limitations of antibody-centric diagnostic frameworks. Histopathologic findings in some seronegative patients-including focal lymphocytic sialadenitis-mirror those seen in pSS, suggesting underlying immune-mediated glandular damage. In others, nonspecific or normal biopsy findings suggest non-immune mechanisms. New evidence of immune activity, such as elevated cytokines (BAFF, IFN-α), and novel autoantibodies (SP-1, CA-VI), further supports the concept of subclinical autoimmunity in a subset of these patients. Clinically, they often face significant burden, including dryness, fatigue, and pain, yet remain excluded from most research cohorts, therapeutic trials, and clinical guidelines. Their management is often individualized, relying on symptomatic therapies rather than immunomodulatory agents. The lack of validated diagnostic criteria and prognostic markers compounds the uncertainty surrounding disease evolution, as some patients may later seroconvert or develop systemic features. To address these gaps, a paradigm shift is needed-one that embraces the spectrum of sicca syndromes, incorporates advanced immunophenotyping, and allows inclusion of seronegative patients in research and care algorithms.
Keywords: autoimmune exocrinopathy; primary Sjögren’s syndrome; seronegative sicca syndrome.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis.Health Soc Care Deliv Res. 2025 Jun;13(24):1-120. doi: 10.3310/HGTQ8159. Health Soc Care Deliv Res. 2025. PMID: 40548558
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
Cited by
-
Amphiregulin and Fibrosis: Existing Evidence and Future Directions.Int J Mol Sci. 2025 Aug 8;26(16):7678. doi: 10.3390/ijms26167678. Int J Mol Sci. 2025. PMID: 40868999 Free PMC article. Review.
References
-
- Shiboski C.H., Shiboski S.C., Seror R., Criswell L.A., Labetoulle M., Lietman T.M., Rasmussen A., Scofield H., Vitali C., Bowman S.J., et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69:35–45. doi: 10.1002/art.39859. - DOI - PMC - PubMed
-
- Brito-Zeron P., Theander E., Baldini C., Seror R., Retamozo S., Quartuccio L., Bootsma H., Bowman S.J., Dörner T., Gottenberg J.-E., et al. Early diagnosis of primary Sjögren’s syndrome: EULAR-SS task force clinical recommendations. Expert Rev. Clin. Immunol. 2016;12:137–156. doi: 10.1586/1744666X.2016.1109449. - DOI - PubMed
-
- Quartuccio L., Baldini C., Bartoloni E., Priori R., Carubbi F., Corazza L., Alunno A., Colafrancesco S., Luciano N., Giacomelli R. Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun. Rev. 2015;14:1019–1022. doi: 10.1016/j.autrev.2015.07.002. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials